Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond strongly to Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy ...
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
A Novo spokesperson said in a statement to Reuters that the new analysis “demonstrates for the first time the benefits of ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
Wegovy, a relatively new drug approved by the US Food and Drug Administration (FDA) in June 2021, mimics the body’s GLP-1 ...
Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk's weight-loss drug ...
Novo Nordisk is already assessing semaglutide’s effects in liver disease linked to obesity — metabolic dysfunction-associated ...